

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-258US

#4

In Re Application Of: MEHTA et al.

Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
31 July 2002	TBA	26815	TBA	TBA

Title:
3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

 Docket No.
 RLL-258US

 In Re Application of: **MEHTA et al.**

	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/523,208	31 July 2002	TBA	26815	TBA	TBA

 Title:
3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS
Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **50-0912** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.
Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

 (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail


I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

 (Date)

 Signature of Person Mailing Correspondence

 Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


 Signature

 Dated: *Sept. 1, 2005*

George E. Heibel
Reg. No. 42,648
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, New Jersey 08540
Tel.: (609) 720-5334
Fax: (609) 514-9779

CC:

Docket No.: RLL 8US

INFORMATION DISCLOSURE CITATION

Applicants: SILAMKOTI *et al.*

Filed: 1/27/2005

Group:

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	3,176,019	3/30/1965	Campbell <i>et al.</i>	260	293.4	
	A2	4,183,857	1/15/1980	Kollmeyer	260	326.5	
	A3	5,281,601	1/25/1994	Cross <i>et al.</i>	514	320	
	A4	5,948,792	9/7/1999	Tsuchiya <i>et al.</i>	514	317	
	A5	6,130,232	10/10/2000	Mase <i>et al.</i>	514	318	
	A6	6,130,241	10/10/2000	Schulz	514	421	
	A7	6,174,900	1/16/2001	Okada <i>et al.</i>	514	317	
	A8	6,313,312	11/6/2001	Banks <i>et al.</i>	548	452	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	B1	EP 0 325 571	7/26/1989	EPO	C07C	215/54		
	B2	EP 0 388 054	9/19/1990	EPO	C07D	207/08		
	B3	EP 0 801 067	10/15/1997	EPO	C07D	453/02		
	B4	GB 940,540	10/30/1963	UK	C07C			
	B5	JP 92921/1994	4/5/1994	Japan	C07C	237/20	Abstract	
	B6	JP 135958/1994	5/17/1994	Japan	C07D	333/16	Abstract	
	B7	WO 91/09013	6/27/1991	PCT	C07D	207/08		
	B8	WO 93/16018	8/19/1993	PCT	C05F	17/02		
	B9	WO 93/16048	8/19/1993	PCT	C07D	211/26		
	B10	WO 96/33973	10/31/1996	PCT	C07D	211/46	US 5,750,540 equivalent	
	B11	WO 97/45414	12/4/1997	PCT	C07D	211/58	Abstract	
	B12	WO 98/05641	2/12/1998	PCT	C07D	211/46	US 5,948,792 equivalent	
	B13	WO 98/29402	7/9/1998	PCT	C07D	311/20		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Docket No.: RLL 8US

Serial No.: 10/523,208

Applicants: SILAMKOTI et al.

JC20 Rec'd PCT/PTO 01 SEP 2005

Filed: 1/27/2005

Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , 323(2):411-416 (1986)
C2	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", <i>Science</i> , 237:527-531 (1987)
C3	Eglen et al., "Muscarinic receptor ligands and their therapeutic potential", <i>Current Opinion in Chemical Biology</i> , 3:426-432 (1999)
C4	Eglen et al., "Therapeutic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , 22(8):409-414 (2001)
C5	Felder et al., "Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , 43(23):4333-4353 (2000)
C6	Broadley and Kelly, "Muscarinic Receptor Agonists and Antagonists", <i>Molecules</i> , 6:142-193 (2001)
C7	Birdsall et al., "Muscarinic receptors: it's a knockout", <i>Trends in Pharmacological Sciences</i> , 22(5):215-219 (2001)
C8	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of Pharmacology and Toxicology</i> , 41:691-721 (2001)
C9	Steers, "The future direction of neuro-urology drug research", <i>Current Opinion in CPNS Investigational Drugs</i> , 2(3):268-282
C10	Chapple, "Muscarinic receptor antagonists in the treatment of overactive bladder", <i>Urology</i> , 55(Suppl. 5A):33-46 (2000)
C11	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology</i> , ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)
C12	Sagara et al, "Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M ₃ Antagonist Discriminating against the Other Receptor Subtypes", <i>Journal of Medicinal Chemistry</i> , 45(4):984-987 (2002)
C13	Vogel's textbook, "Practical Organic Chemistry" 1046-1047 (5th Ed.)
C14	Grover et al., "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", <i>Journal of Organic Chemistry</i> , 65:6283-6287 (2000)
C15	Cheng and Prusoff, "Relationship between the inhibition constant (K ₁) and the concentration of inhibitor which causes 50 per cent inhibition (I ₅₀) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , 22:3099-3108 (1973)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.